Interview withTeresa Pallotta, Sales & Marketing Director at CordenPharma, a full-service Contract Development and Manufacturing Organisation (CMO) which serves the Global Pharmaceutical Industry with APIs and Drug Products

Giovanni Bernuzzi

CordenPharma was formed in 2006 as a pharmaceutical brand of International Chemical Investors Group (ICIG), a privately-owned industrial group focused on mid-sized chemical & pharmaceutical businesses, with 18 operating companies, 19 manufacturing plants worldwide, over 3,500 employees and approximately €800 million in total sales. Since inception, CordenPharma has grown into a full-service CMO partner in the cGMP Contract Development & Manufacturing of pharmaceutical Drug Products, their Active Pharmaceutical Ingredients (APIs), and associated Packaging Services.

“Through strategic acquisitions of multiple cGMP facilities across Europe and the USA from top pharmaceutical and biotechnology companies – saysTeresa Pallotta, Sales & Marketing Director – CordenPharma is linking together a legacy of high-caliber scientists, technologies, and capabilities, originated from innovative pharmaceutical companies, to provide balanced outsourcing. Through our network of facilities, we globally supply customers with fully-integrated, cost-effective pharmaceutical development and custom manufacturing services covering the whole value chain – starting from non-cGMP API intermediates to fully cGMP commercial scale – from APIs to finished dosage forms.”

CordenPharma: Your Path to Balanced Outsourcing

Our network of fully-audited facilities, stringent quality systems, and integrated project management teams – statesTeresa Pallotta- provide customers flexible solutions to reduce the need for repeated technology transfer throughout various project phases, which often includes management of fragmented supply chains or diversified best practices from multiple suppliers, thereby bringing efficient balance to the outsourcing process. Our customized set of complementary technologies in small and large-scale API production, drug product formulation development and manufacturing, and advanced packaging services greatly decreases overall development time to market, while at the same time surpasses the standards required for customers’ product success.